Non-Hodgkin Lymphoma

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

Selinexor monotherapy induced deep and durable responses in the phase IIb SADAL study of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

The addition of brentuximab vedotin to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma.

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma.

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.